Aclasta patient information: 

Aclasta patient information: The osteoporosis prescription drug, Aclasta, is distributed in Europe and in Australia. In the United States, Acalsta is sold under the name name, Reclast. Reclast is the exact same drug as Aclasta.

More Aclasta patient information.  This Osteoporosis drug is a form of zolendronic acid. Zolendronic acid belongs to a class of drugs called bisphosphonates.  Like all bisphosophonates, Aclasta slows the rate at which 'old bone' is removed by your body.  Since old bone is not being removed, bone density increases.                                                                                                                                                          Taking this drug. With Acasta there is NO daily pill to take. Instead you go to your doctor's office once a year. They set up an IV of Aclasta and it goes directly into your vein. Then you go home. Done.   No daily or weekly pills to remember.  Many              patients prefer this medication to other Osteoporosis drug because of this once a year treatment. You make your appointment, go to the office, have your infusion and your Osteoporosis treatment is done until next year.

Continuation Aclasta patient information. Aclasta is also sold under the name Reclast. Agin, this Osteoporosis treatment appeals to those who prefer not to take daily or weekly pills. There is nothing to remember with this drug! (Most doctors' office staff are willing to keep track of your treatment date and call you when it is time for you to make an appointment and come in for your annual infusion.) You go in, have your infusion and then go home to live your life.

Now, if you are considering Aclasta for treating your Osteoporosis, you will want to know a bit more, so read on....... 


What company makes Aclasta ? Are they well known?

Novartis,  one of the largest pharmaceutical companies in the world, is the company that makes Aclasta.   They  developed the drug and did all the necessary research studies before the drug could be approved and brought to market. They are also the company that provides all the Aclasta patient information.

Scientific studies. One study of Aclasta was  The Pivotal Fracture Trial  . It showed that Aclasta increased bone strength and reduced fractures of the hip, spine and other areas such as wrists, arms, legs and/or ribs. After that Pivotal Fracture Trial, the drug was approved for use by those who had Osteoporosis. 

More Aclasta patient information: Note that the Pivotal Fracture Trial showed that Aclasta appeared to be effective in reducing fractures, which is the main reason why anyone treats Osteoporosis. No one wants a fracture because their bones have become thinnerand  weaker as a result of age or one of other Causes of Osteopenia, Osteoporosis  (Note: If you have not checked out all the possible causes of your bone loss, I encourage you to do so. You might find something you can change easily.)

When Aclasta was approved, it was the only drug that had been shown to reduce fractures at ALL the key sites where Osteoporosis fractures usually occur: hips, spine, wrists, arms, legs and ribs. As a result Aclasta was seen as a big advance in the treatment of Osteopenia or Osteoporosis.                                                                                                                                                                                                Note: If you are concerned about having one of the small spinal fractures that can cause back hump (See: dowagers humps, ) you may want to know that the New England Journal of Medicine reported in May 2007 that a study involving more than 7,700 women, showed that treatment with Aclasta reduced the risk of spinal fractures by 70% AND Aclasta also reduced hip fractures by 41%.

The reduction in spinal fractures for the three years of the study was as follows: 60% reduction in year one; 71% in year two and 70% in year three. Those are significant numbers! -- especially when we consider that bone loss in the spine usually leads to kyphosis (or dowagers hump)  - an unsightly and often debilitating condition. 

Additional Aclasta patient information:

Additional Aclasta patient information.  Novatis, the company that manufactures Aclasta,  states in that this drug: 

      "has shown significant efficacy in protecting women against fractures in all the            common osteoporotic fracture sites, while demonstrating a favorable safety                profile. It is our hope that this innovative once-yearly dosing regimen will have a          positive impact on the management of this potentially devastating condition." 

Also, with that  same Aclasta patient information,  Novartis says that Aclasta  "is indicated for treatment of osteoporosis in postmenopausal women. In patients with a recent low-trauma hip fracture".. and that this drug.. "reduces the incidence of new clinical fractures".   

If you are considering getting this annual drug infusion, you may be interested in additional Aclasta patient information:

  • Aclasta is including those with a recent low-trauma hip fracture."
  • And it is "indicated for treatment of osteoporosis associated with long-term systemic glucocorticoid therapy in postmenopausal women and in men with increased risk of fracture" and 
  • "Aclasta is indicated for the treatment of Paget's disease of the bone."

Other advantages of Aclasta. Many in the health care community believe that once a year infusions are the helpful for patients because they offer a remedy for the inconvenience of daily, weekly or monthly Osteoporosis medications.  Also annual infusions eliminate one of the main problems of daily or monthly medications - that many people just stop taking their prescribed medication!                                        (This failure to take medication is called 'non-compliance' by the medical community and it has been shown that Osteoporosis medication non-compliance with daily or weekly pills is high. Aclasta reduces this non-compliance rate.)


Alcasta patient information: Drug side effects

Aclasta patient information: Side Effects. Note: Since this drug is sold under various names in different countries, these same side effects apply to its other forms such as, Reclast.  (In fact, if you live in the United States, the Novartis site will direct you to a page about Reclast, not Aclasta)

Since this is a bisphosphonate drug Novartis is careful to mention in their Aclasta  patient information that is a possibility of developing Osteonecrosis. (Click for information about: Osteonecrosis ).                                                                                             The company also states in its Aclasta patient information that:"Disturbances of mineral metabolism must be treated before starting therapy. Patients must be adequately supplemented with calcium and vitamin D." Also, "a single  dose of Aclasta should not exceed 5 mg and infusion time should be no less than 15 minutes." 

Side effects: A study published in March of 2013, showed a serious side effect with this drug: Acute kidney injury. If you want to  read a summary of that study click the link for: Journal of Oncology Practice.

To read about other potential side effects as well as a list of medical conditions that would preclude you from using this drug go to: Aclasta Patient Information: Reclast side effects 

There is even more Aclasta patient information, including some you can print out to take with your to your visit with your health care provider, at:  Aclasta, Reclast Research Studies                                                                     

NOTE: If you have used this drug and  want to leave a comment about your experience on this Aclasta patient information page, please scroll down to find the form you can use.  Your comment may help another reader of considering this Osteoporosis treatment.  I thank you in advance for sharing. 

End of Aclasta Information. 

Information about other medications for low bone density can be found at:          Osteopenia and Osteoporosis medications

If in addition to this Aclasta information, you may be interested in natural treatments for building stronger bones, Go to Natural Osteopenia, Osteoporosis Treatments

NOTE: This web site offers science based information, such as the Aclasta information given above. The web site does not offer medical advice at any time. For medical advice you need to consult your licensed medical practitioner.

We have a FREE monthly newsletter with updates about Osteopenia and Osteoporosis treatments as well as encouragement to women and men with these conditions. Click to subscribe to the Osteopenia3 updates newsletter 

  Go  to: HOME 


Aclasta Information: Reader comments

1. From Jeanne in Adelaide South Australia.

SPECIAL NOTE: If you have used Aclasta and would like to leave a comment about your experience, please use the  form below. Please be sure to put the word Aclasta at the beginning of your comment so I know which page you are commenting on. (I use the same form for all pages.) If you do not put Aclasta information or  Zolendronic acid information at the top of your response, I shall not be able to add your comments to this page. Thanks.

Have you experience with this?

Do you have experience with this? Please share it!

[ ? ]

Upload 1-4 Pictures or Graphics (optional)[ ? ]

 

Click here to upload more images (optional)

Author Information (optional)

To receive credit as the author, enter your information below.

(first or full name)

(e.g., City, State, Country)

Submit Your Contribution

  •  submission guidelines.


(You can preview and edit on the next page)

What Other Visitors Have Said

Click below to see contributions from other visitors to this page...

Jean in Adelaide, South Australia Not rated yet
On 23 January 2018 I had my first infusion of Aclasta. I felt fine for around 15 hours afterwards and then developed the flu like symptoms I was warned …

Aclasta reaction Not rated yet
I had aclasta on a Tuesday afternoon that night I started shaking and felt like I had been transported to the Antartic. Muscle pain in the back and legs …

Click here to write your own.